Solid Biosciences (SLDB) CFO awarded 56,647 RSUs after performance milestone

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Solid Biosciences Inc. reported that CFO & Treasurer Kevin Tan acquired 56,647 restricted stock units tied to prior performance-based awards. Each unit represents a contingent right to receive one share of common stock, bringing his directly held RSU-based position reported in this filing to 56,647 units.

These RSUs relate to performance stock units granted on June 11, 2024, which vest in four equal 25% tranches upon achieving predetermined, non-market and non-financial performance milestones. The second milestone was certified as achieved on January 29, 2026, with the associated shares scheduled to vest only if he remains in service through an evaluation date anticipated in the first quarter of 2027.

Insider Trade Summary 10b5-1

1 transaction reported

Mixed 1 txn

Insider Tan Kevin

Role CFO & Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	56,647	$0.00	--

Holdings After Transaction: Restricted Stock Units — 56,647 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

Key Figures

RSUs acquired: 56,647 units Underlying common shares: 56,647 shares Performance milestones: 4 milestones +4 more

7 metrics

RSUs acquired 56,647 units Restricted stock units acquired on January 29, 2026

Underlying common shares 56,647 shares Each RSU equals one share of common stock

Performance milestones 4 milestones PSUs vest in four independent performance milestones

Tranche per milestone 25% of target RSUs Each milestone vests 25% of target underlying RSUs

PSU grant date June 11, 2024 Original grant date of performance stock units

Milestone 2 achievement January 29, 2026 Date Board determined second milestone was met

Expected vesting timing Q1 2027 Evaluation date anticipated in first quarter of 2027

Key Terms

Restricted Stock Units, Performance stock units ("PSUs"), performance milestones, non-market and non-financial in nature, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Performance stock units ("PSUs") financial

"Performance stock units ("PSUs") were granted on June 11, 2024"

performance milestones financial

"vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones"

non-market and non-financial in nature financial

"Performance Milestones are tied to the achievement of certain business objectives... and are non-market and non-financial in nature"

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share"

Form 4 Insider Transactions: What Each Field Means →

04/21/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tan Kevin

(Last)

(First)

(Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN

MASSACHUSETTS

02129

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO & Treasurer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	01/29/2026		A		56,647		⁽²⁾	⁽²⁾	Common Stock	56,647	$0.00	56,647	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

2. Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

	/s/ Kimberly Cornwell as attorney-in-fact for Kevin Tan	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Solid Biosciences (SLDB) CFO Kevin Tan report in this Form 4?

Kevin Tan reported an acquisition of 56,647 restricted stock units. These units stem from earlier performance stock unit grants and each represents a contingent right to receive one share of Solid Biosciences common stock, subject to future vesting conditions and continued service requirements.

How many restricted stock units did the SLDB CFO receive in this transaction?

The CFO received 56,647 restricted stock units. Each RSU corresponds to one share of common stock, and this amount matches the total RSU-based holdings reported following the transaction in the filing, reflecting the portion tied to an achieved performance milestone.

What are the terms of the performance stock units mentioned for Solid Biosciences (SLDB)?

The performance stock units were granted on June 11, 2024, and are linked to four independent performance milestones. Each milestone triggers vesting of 25% of the target underlying restricted stock units when its non-market, non-financial performance criteria are certified as achieved by the Board.

Which performance milestone was achieved for Solid Biosciences (SLDB) in this Form 4?

The second performance milestone was determined by the Board to be met on January 29, 2026. This achievement unlocked the related portion of underlying restricted stock units, subject to the executive’s continued service through a specified future evaluation date for vesting.

When are the vested shares from this SLDB performance milestone expected to be delivered?

The shares related to the second performance milestone are expected to vest on an evaluation date anticipated in the first quarter of 2027. Actual vesting remains contingent on the grantee’s continued service with Solid Biosciences through that evaluation date.

How are the performance milestones structured for SLDB’s performance stock units?

There are four independent performance milestones, each tied to specific business objectives. Upon certification that a milestone is achieved, 25% of the target number of underlying restricted stock units is earned, using criteria that are explicitly described as non-market and non-financial in nature.